Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adulterated, Angkustsiri, arrive, ATM, bid, biosimilar, blocking, compelling, conflict, consecutive, dampening, delist, delisting, digital, DSCSA, greatest, Hong, inflation, influenza, inhibitory, IRA, Kathy, Kong, leaning, Lincoln, LPI, lysophosphatidylinositol, MAS, membrane, Mexico, misrepresentation, MMA, nonclinical, pack, pallet, Park, phospholipid, recessionary, regain, resurgence, RSV, Russia, Simon, sovereign, syncytial, Tony, transformation, tripledemic, Ukraine, unfit, workplace, Young
Removed:
ABA, accelerating, al, altered, anecdotal, antipsychotic, aripiprazole, Asperger, autistic, billion, cellular, complaint, Confluence, Connecticut, DEE, diagnostic, District, DSCA, dysregulation, energy, epilepsy, epileptic, Explanation, extracted, finally, foregoing, Foundation, GABAergic, globally, glutamatergic, hearing, inform, intervention, Manual, misleading, modulate, Nevada, NFXF, numerical, occupational, oxidative, plaintiff, plant, pocket, purportedly, putative, qualifying, Reauthorization, relate, researched, risperidone, secure, Select, show, strain, structured, trillion, unconsolidated, verbal
Filing tables
Filing exhibits
Related press release
ZYNE similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements on Form S-3 (No. 333-264966) and Form S-8 (Nos. 333-263128, 333-256028, 333-237051, 333-230182, 333-223597, 333-216968, 333-216967, and 333-207973) of our report dated March 28, 2023, with respect to the consolidated financial statements of Zynerba Pharmaceuticals, Inc.
/s/ KPMG LLP |
Philadelphia, Pennsylvania |
March 28, 2023 |